Vir Biotechnology shares rise 1.77% after-hours following Raymond James' Outperform rating.

Friday, Jul 11, 2025 5:16 pm ET1min read
Vir Biotechnology, Inc. rose 1.77% in after-hours trading, following the news that Raymond James initiated coverage on the company with an "Outperform" rating. The company is focused on developing treatments for serious infectious diseases and other conditions, with a pipeline that includes candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV).

Vir Biotechnology shares rise 1.77% after-hours following Raymond James' Outperform rating.

Comments



Add a public comment...
No comments

No comments yet